XML 114 R57.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment - Divestitures (Details) - USD ($) $ / shares in Units, shares in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Oct. 31, 2018 | Sep. 30, 2018 | Apr. 30, 2018 | Dec. 31, 2018 | Jul. 01, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2014 | Feb. 03, 2017 | Oct. 06, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain representing difference between fair value of equity investment and book value of assets transferred | [2] |  |  |  |  |  | $ 586,000,000 | [1] | $ 224,000,000 |  | $ 18,000,000 |  |  |
Income (loss) on sale of assets | [3],[4] |  |  |  |  |  | 1,000,000 |  | (55,000,000) |  | (1,712,000,000) |  |  |
Equity securities |  |  |  |  | $ 1,600,000,000 |  | 1,600,000,000 |  | 2,150,000,000 |  |  |  |  |
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Book value of assets transferred |  |  |  |  | 9,725,000,000 |  | 9,725,000,000 |  | 12,000,000 |  |  |  |  |
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment charge for HIS net assets |  |  |  |  |  |  |  |  |  |  | $ 1,700,000,000 |  |  |
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Consumer Healthcare [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Book value of assets transferred |  |  |  |  | 9,678,000,000 |  | 9,678,000,000 |  | 0 |  |  |  |  |
Disposed of by Sale, Not Discontinued Operations [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and common stock to be received for disposition |  |  |  | $ 75,000,000 | 85,000,000 |  | 85,000,000 |  |  |  |  |  |  |
Maximum amount of milestone payments to be received |  |  |  | $ 515,000,000 |  |  |  |  |  |  |  |  |  |
ICU Medical [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and common stock to be received for disposition |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000,000
ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and common stock to be received for disposition |  |  |  |  |  |  |  |  |  |  |  |  | $ 900,000,000 |
Shares of common stock received for disposal |  |  |  |  |  |  |  |  |  |  |  |  | 3.2 |
Value of common stock received for disposal |  |  |  |  |  |  |  |  |  |  |  |  | $ 428,000,000 |
Gain from sale of shares |  |  |  |  |  |  | 302,000,000 |  |  |  |  |  |  |
Gain representing difference between fair value of equity investment and book value of assets transferred |  |  |  |  |  |  | 47,000,000 |  |  |  |  |  |  |
Consideration receivable |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000 |
Cash proceeds from disposal |  |  |  |  |  |  |  |  | 200,000,000 |  |  |  |  |
Maximum contingent consideration |  |  |  |  |  |  |  |  |  |  |  |  | $ 225,000,000 |
Income (loss) on sale of assets |  |  |  |  |  |  | 1,000,000 |  | $ (55,000,000) | [5] |  |  |  |
Cellectis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  | 7.00% |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000 |  |
Allogene [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  | 18.00% |  | 25.00% |  |  |  |  |  |  |  |  |  |
Gain from contribution agreement |  |  |  |  |  | $ 50,000,000 | 50,000,000 |  |  |  |  |  |  |
Cerevel [Member] | Bain Capital [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain representing difference between fair value of equity investment and book value of assets transferred |  |  | $ 343,000,000 |  |  |  | 343,000,000 |  |  |  |  |  |  |
Cerevel [Member] | Bain Capital [Member] | Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member] | Neuroscience Assets [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Committed investment from collaborator |  |  |  |  | 350,000,000 |  | 350,000,000 |  |  |  |  |  |  |
Book value of assets transferred |  |  |  |  | 0 |  | 0 |  |  |  |  |  |  |
Long-term Investments [Member] | Allogene [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity securities |  |  |  |  | 127,000,000 |  | $ 127,000,000 |  |  |  |  |  |  |
Allogene [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price (in dollars per share) |  | $ 25 |  |  |  |  |  |  |  |  |  |  |  |
Other Nonoperating Income (Expense) [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash and common stock to be received for disposition |  |  |  |  |  | $ 75,000,000 |  |  |  |  |  |  |  |
Milestone payment recognized |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |
Cerevel Therapeutics [Member] | Cerevel [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |
[1] | The net gains on investments in equity securities are reported in Other (income)/deductions––net and, for 2018, include unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. For additional information, see Note 4.
[2] | The net gains on investments in equity securities in 2018, include unrealized net gains on equity securities of $477 million, reflecting the adoption of a new accounting standard in the first quarter of 2018. Net gains in 2018 were primarily driven by unrealized gains of $466 million related to our investment in Allogene. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B, Note 2B and Note 7B.
[3] | Amounts may not add due to rounding.
[4] | In 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information.
[5] | Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In 2018, primarily includes, among other things, (i) approximately $118 million in milestone income from multiple licensees, (ii) $110 million in milestone payments received from Shire, of which $75 million was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and $35 million was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn’s disease, (iii) an upfront payment to us and a recognized milestone totaling $85 million for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) $62 million in gains related to sales of compound/product rights and (v) a $40 million milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see Note 2B, Note 2C, Note 2D and Note 2E. In 2017, primarily includes, among other things, $101 million in milestone payments received from multiple licensees and an $85 million gain related to sales of compound/product rights. In 2016, primarily includes, among other things, a $50 million gain related to sales of compound/product rights and $33 million in milestone payments received from multiple licensees.

X
- Definition Collaborative Arrangement, Committed Investment From Collaborator, Amount + References No definition available. + Details
Name: | pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disposal Group, Including Discontinued Operation, Consideration, Note Receivable + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares
Namespace Prefix: | pfe_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Disposal Group, Including Discontinued Operation, Contingent Consideration + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disposal Group, Including Discontinued Operation, Milestone + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationMilestone
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value + References No definition available. + Details
Name: | pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gain (Loss) From Contribution Agreement + References No definition available. + Details
Name: | pfe_GainLossFromContributionAgreement
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Impairment on Remeasurement of Assets to be Disposed Of + References No definition available. + Details
Name: | pfe_ImpairmentonRemeasurementofAssetstobeDisposedOf
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Investment, Ownership Percentage + References No definition available. + Details
Name: | pfe_InvestmentOwnershipPercentage
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments To Collaborators + References No definition available. + Details
Name: | pfe_PaymentsToCollaborators
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount classified as assets attributable to disposal group held for sale or disposed of. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760 + Details
Name: | us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiRealizedGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_ICUMedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CellectisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_BainCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_NeuroscienceAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=pfe_AllogeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=pfe_CerevelTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |